SOTAC PHARMACEUTICALS
|
The Current P/E Ratio of SOTAC PHARMACEUTICALS is 39.62.
| Share Price | ₹135.0 | Nov 20,2026 |
| Market Cap | ₹149.9 Cr | |
| Earnings-TTM | ₹3.8 Cr | TTM-Consolidated Results |
| Price/Earnings | 39.62x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of SOTAC PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹149.9 Cr] as on Nov 20,2026
(/) Earnings [ ₹3.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 39.62x ]
Thus, for SOTAC PHARMACEUTICALS , the investors are currently willing to pay 39.62 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of SOTAC PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of SOTAC PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of SOTAC PHARMACEUTICALS
PE Ratio Performance Analysis for SOTAC PHARMACEUTICALS
- SOTAC PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 13.70x.
- SOTAC PHARMACEUTICALS 's operated at median p/e ratio of 16.35x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, SOTAC PHARMACEUTICALS 's p/e ratio peaked in Mar2024 at 31.23x.
- SOTAC PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2023 of 0x.
How does SOTAC PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| SOTAC PHARMACEUTICALS | 3.78 | 39.62 | 149.9 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,037.20 | 40.98 | 452,299.0 |
| DIVIS LABORATORIES LTD | 3,363.00 | 88.41 | 297,325.0 |
| TORRENT PHARMACEUTICALS LTD | 2,099.00 | 85.15 | 178,727.0 |
| CIPLA LTD | 2,868.29 | 39.85 | 114,312.0 |
| DR REDDYS LABORATORIES LTD | 2,759.70 | 42.09 | 116,145.0 |
| MANKIND PHARMA LTD | 2,249.69 | 48.84 | 109,880.0 |
| LUPIN LTD | 5,221.47 | 17.60 | 91,915.9 |
| ZYDUS LIFESCIENCES LTD | 4,159.00 | 28.66 | 119,207.0 |
| AUROBINDO PHARMA LTD | 3,993.05 | 25.87 | 103,298.0 |
| LAURUS LABS LTD | 1,333.75 | 92.97 | 124,002.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs SOTAC PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.60x |
| Max industry PE | 92.97x |
| Median industry PE | 40.98x |
| Average industry PE | 50.00x |
You may also like the below Video Courses